Key result
Pandemic-era evaluation linked to ~6.5-fold higher incidence of cancer therapy-related cardiac dysfunction.
Why the study?
The COVID-19 pandemic significantly altered cardiology practice and healthcare organization, but its impact on the development of cancer therapy-related cardiac dysfunction remained unclear.
Does the COVID-19 pandemic era and associated reduction in cardiological surveillance increase the incidence of cancer therapy-related cardiac dysfunction (CTRCD) in cancer patients treated with anthracyclines compared to the pre-pandemic era?
Cohort (n=156)
No
Does the COVID-19 pandemic era and associated reduction in cardiological surveillance increase the incidence of cancer therapy-related cardiac dysfunction (CTRCD) in cancer patients treated with anthracyclines compared to the pre-pandemic era?
Reduced cardiological surveillance and delayed hospital access during the COVID-19 pandemic were associated with a significantly higher incidence of anthracycline-related cardiac dysfunction (13% vs. 2%), underscoring the necessity of maintaining regular cardio-oncology monitoring and GLS echocardiography.
Answers are grounded in this paper and cite their sources.
Pandemic-era evaluation was associated with higher CTRCD incidence; leaves open surveillance impact and requires prospective confirmation.
Aim: COVID-19 pandemic had a big impact on our life, it has revolutionized the practice of cardiology and the organization of hospital and outpatient activities. Thus the aim of our study was to assess the impact of the COVID-19 pandemic on the development of cancer therapy-related cardiac dysfunction (CTRCD). Methods and results: A single center retrospective study was carried out evaluating 96 cancer patients treated with anthracyclines and admitted to our Cardio-Oncology unit from June to August 2019 and 60 patients from June to August 2021. The incidence of CTRCD was assessed performing an echocardiogram at the time of the enrollment. We found a significantly higher incidence of CTRCD in the second period compared to first period (13% vs. 2%, p value 0.0058). In addition we found that fewer yearly visits were performed in our Cardio-oncology unit in 2021 compared to 2019 (300 patients/year in 2019 vs. 144 patients/year in the COVID era). Conclusion: COVID-19 pandemic seems to influence the onset of CTRCD in cancer patients by indirectly reducing hospital access of cancer patients and cardiological checks. In addition our data reflect the impact of the COVID-19 pandemic in the late diagnosis of cancer, in the reduction of hospital admissions and regular medical checks, in the increase of comorbidities and cardiovascular complications.
No takes yet. Share an insight, caveat, or question.
Lisi et al. (2023) conducted a cohort in Cancer (lymphoma or breast cancer) treated with anthracyclines (n=156). COVID-19 pandemic era care (June to August 2021, reduced surveillance and focused echocardiography without routine GLS) vs. Pre-COVID-19 pandemic care (June to August 2019, rigorous surveillance with echocardiography and GLS every 3 months) was evaluated on Incidence of cancer therapy-related cardiac dysfunction (CTRCD) assessed by echocardiogram at enrollment (p=0.0058). Evaluation during the COVID-19 pandemic era was associated with a significantly higher incidence of cancer therapy-related cardiac dysfunction compared to the pre-pandemic era (13% vs. 2%, p=0.0058).
Synapse has enriched 10 related papers. Consider them for comparative context: